{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:49:18Z","timestamp":1788580158612,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-025-03262-w","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:39:20Z","timestamp":1762447160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Influence of pH and Preservative Agents on Physicochemical and Microbiological Stability of a Flexible Dose\/Age-Appropriate Formulation of Enalapril Maleate. A Quality by Design\u2011Based Optimization"],"prefix":"10.1208","volume":"27","author":[{"given":"Mauro","family":"Morri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Alejandra","family":"Operto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-3570","authenticated-orcid":false,"given":"Dar\u00edo","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Vignaduzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"3262_CR1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.2165\/00003495-198631030-00002","volume":"31","author":"PA Todd","year":"1986","unstructured":"Todd PA, Heel RC. Enalapril. Drugs. 1986;31:198\u2013248.","journal-title":"Drugs"},{"key":"3262_CR2","doi-asserted-by":"crossref","unstructured":"Li JJ.  Medicinal chemistry for practitioners. Hoboken: Wiley; 2020. p. 416.","DOI":"10.1002\/9781119607311"},{"key":"3262_CR3","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.xphs.2017.04.019","volume":"106","author":"RK Verbeeck","year":"2017","unstructured":"Verbeeck RK, Kanfer I, L\u00f6benberg R, et al. Biowaiver monographs for immediate-release solid oral dosage forms: enalapril. J Pharm Sci. 2017;106:1933\u201343.","journal-title":"J Pharm Sci"},{"key":"3262_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061163","volume":"14","author":"S Laeer","year":"2022","unstructured":"Laeer S, Cawello W, Burckhardt BB, et al. Enalapril and enalaprilat pharmacokinetics in children with heart failure due to dilated cardiomyopathy and congestive heart failure after administration of an orodispersible enalapril minitablet (LENA-studies). Pharmaceutics. 2022;14: 1163.","journal-title":"Pharmaceutics"},{"key":"3262_CR5","unstructured":"EMA. Aqumeldi : EPAR - medicine overview. In: Aqumeldi An Overv. Aqumeldi why it is Auth. EU;\u00a02023.\u00a0https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/aqumeldi ( Aqumeldi es un producto farmac\u00e9utico aprobado por la EMA)."},{"key":"3262_CR6","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1016\/j.drudis.2020.08.005","volume":"25","author":"NJL Smeets","year":"2020","unstructured":"Smeets NJL, Schreuder MF, Dalinghaus M, Male C, Lagler FB, Walsh J, Laer S, de Wildt SN. Pharmacology of enalapril in children: a review. Drug Discov Today. 2020;25:1957\u201370.","journal-title":"Drug Discov Today"},{"key":"3262_CR7","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1093\/ajhp\/55.11.1155","volume":"55","author":"MC Nahata","year":"1998","unstructured":"Nahata MC, Morosco RS, Hipple TF. Stability of enalapril maleate in three extemporaneously prepared oral liquids. Am J Health Pharm. 1998;55:1155\u20137.","journal-title":"Am J Health Pharm"},{"key":"3262_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106377","volume":"182","author":"EA Kean","year":"2023","unstructured":"Kean EA, Adeleke OA. Orally disintegrating drug carriers for paediatric pharmacotherapy. Eur J Pharm Sci. 2023;182: 106377.","journal-title":"Eur J Pharm Sci"},{"key":"3262_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ijpharm.2016.03.017","volume":"512","author":"SM Hanning","year":"2016","unstructured":"Hanning SM, Lopez FL, Wong ICK, Ernest TB, Tuleu C, OGM. Patient centric formulations for paediatrics and geriatrics: similarities and differences. Int J Pharm. 2016;512:355\u20139.","journal-title":"Int J Pharm"},{"key":"3262_CR10","first-page":"488","volume":"9","author":"WA Malkawi","year":"2022","unstructured":"Malkawi WA, AlRafayah E, AlHazabreh M, AbuLaila S, Al-Ghananeem AM. Formulation challenges and strategies to develop pediatric dosage forms. Children (Basel). 2022;9:488.","journal-title":"Children (Basel)"},{"key":"3262_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103766","volume":"28","author":"Y Mu","year":"2023","unstructured":"Mu Y, Zhao L, Shen L. Medication adherence and pharmaceutical design strategies for pediatric patients: an overview. Drug Discov Today. 2023;28: 103766.","journal-title":"Drug Discov Today"},{"key":"3262_CR12","doi-asserted-by":"publisher","first-page":"103154","DOI":"10.1016\/j.jddst.2022.103154","volume":"70","author":"K Miyazaki","year":"2022","unstructured":"Miyazaki K, Hida N, Kamiya T, et al. Comparative acceptability of mini-tablets, fine granules, and liquid formulations in young children: an exploratory randomized crossover study. J Drug Deliv Sci Technol. 2022;70:103154.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3262_CR13","doi-asserted-by":"publisher","unstructured":"Rajpoot K, Tekade RK, Chatterjee B, Sharma MC, Tekade M. Biopharmaceutical considerations in the pediatric and geriatric formulation development. In: Biopharmaceutics and pharmacokinetics considerations. Elsevier; 2021. pp. 109\u2013144. https:\/\/doi.org\/10.1016\/B978-0-12-814425-1.00017-6.","DOI":"10.1016\/B978-0-12-814425-1.00017-6"},{"key":"3262_CR14","unstructured":"Sharma SM, Sharma R, Chandrateya P, Sardana S. Advancing drug chemical stability: unravelling recent developments and regulatory considerations. Pharmaceutical Regulatory Affairs: Open Access. 2024;13:02."},{"key":"3262_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1208\/s12249-017-0875-1","volume":"19","author":"H Dao","year":"2018","unstructured":"Dao H, Lakhani P, Police A, Kallakunta V, Ajjarapu SS, Wu K-W, Ponkshe P, Repka MA, Narasimha Murthy S. Microbial stability of pharmaceutical and cosmetic products. AAPS PharmSciTech. 2018;19:60\u201378.","journal-title":"AAPS PharmSciTech"},{"key":"3262_CR16","unstructured":"Sandle TP. Pharmaceutical microbiology: essentials for quality assurance and quality control. Elsevier; 2016."},{"key":"3262_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/10837450802244686","volume":"13","author":"L Kumar","year":"2008","unstructured":"Kumar L, Amin A, Bansal A. Preparation and characterization of salt forms of Enalapril. Pharm Dev Technol. 2008;13:345\u201357.","journal-title":"Pharm Dev Technol"},{"key":"3262_CR18","doi-asserted-by":"publisher","first-page":"106121","DOI":"10.1016\/j.ejps.2022.106121","volume":"171","author":"MR Bout","year":"2022","unstructured":"Bout MR, Vromans H. Influence of commonly used excipients on the chemical degradation of enalapril maleate in its solid state: the role of condensed water. Eur J Pharm Sci. 2022;171:106121.","journal-title":"Eur J Pharm Sci"},{"key":"3262_CR19","doi-asserted-by":"crossref","unstructured":"Ip DP, Brenner GS. Enalapril Maleate. Anal Profiles Drug Subs. 1978;16:207\u2013243.","DOI":"10.1016\/S0099-5428(08)60557-2"},{"key":"3262_CR20","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0731-7085(01)00399-5","volume":"25","author":"M Al-Omari","year":"2001","unstructured":"Al-Omari M, Abdelah M, Badwan A, Jaber AM. Effect of the drug-matrix on the stability of enalapril maleate in tablet formulations. J Pharm Biomed Anal. 2001;25:893\u2013902.","journal-title":"J Pharm Biomed Anal"},{"key":"3262_CR21","unstructured":"European-pharmacopoeia. https:\/\/www.edqm.eu\/en\/european-pharmacopoeia. Accessed 24 June 2025."},{"key":"3262_CR22","unstructured":"States Pharmacopeial Convention. The United States Pharmacopeia. 38th ed.. The National Formulary. 33rd ed. Rockville: United States Pharmacopeial Convention; 2015."},{"key":"3262_CR23","doi-asserted-by":"crossref","unstructured":"Desu H, Narang A, Kumar V, Thoma L, Mahato R RI. Chapter 10 - Liquid Dosage Forms. In: Dash AK, Singh S, editors. Pharm Second Ed [Internet]. Academic Press; 2024 [cited 2024 Jul 3]. pp. 271\u2013318. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780323997966000072.","DOI":"10.1016\/B978-0-323-99796-6.00007-2"},{"key":"3262_CR24","first-page":"21","volume":"1","author":"D Gupta","year":"2024","unstructured":"Gupta D, Bhatt S, Pranki Shukla AK. Microbial contamination in pharmaceutical manufacturing. J Drug Discov Heal Sci. 2024;1:21\u20137.","journal-title":"J Drug Discov Heal Sci"},{"key":"3262_CR25","unstructured":"(ICH) International Conference On Harmonisation, Q1A (R2) Stability testing of new drug substances and drug products. In: 2003. https:\/\/www.ema.europa.eu\/en\/ich-q1a-r2-stability-testing-new-drug-substances-drug-products-scientific-guideline%0A.\u00a0Accessed 20 June 2025."},{"key":"3262_CR26","doi-asserted-by":"publisher","first-page":"122193","DOI":"10.1016\/j.ijpharm.2022.122193","volume":"626","author":"VL Beraldo-Ara\u00fajo","year":"2022","unstructured":"Beraldo-Ara\u00fajo VL, Fl\u00e1via Siqueira Vicente A, van Vliet Lima M, Umerska A, Souto EB, Tajber L, Oliveira-Nascimento L. Levofloxacin in nanostructured lipid carriers: preformulation and critical process parameters for a highly incorporated formulation. Int J Pharm. 2022;626:122193.","journal-title":"Int J Pharm"},{"key":"3262_CR27","doi-asserted-by":"publisher","first-page":"106651","DOI":"10.1016\/j.clay.2022.106651","volume":"228","author":"N Suterio","year":"2022","unstructured":"Suterio N, Bazzo GC, Rauber GS, Silva AH, Caon T, Parize AL, Creczynski-Pasa TB, Stulzer HK. Laponite\u00ae gel formulation containing simvastatin for melanoma treatment. Appl Clay Sci. 2022;228:106651.","journal-title":"Appl Clay Sci"},{"key":"3262_CR28","first-page":"122","volume":"2","author":"A Khan","year":"2024","unstructured":"Khan A, Naquvi KJ, Haider MF, Khan MA. Quality by design- newer technique for pharmaceutical product development. Intell Pharm. 2024;2:122\u20139.","journal-title":"Intell Pharm"},{"key":"3262_CR29","doi-asserted-by":"publisher","unstructured":"Comoglu T, Ozyilmaz ED. Pharmaceutical product development: a \u201cquality by design\u201d(QbD) approach. In: Dosage forms, formulation developments and regulations. Elsevier; 2024. pp. 285\u2013310. https:\/\/doi.org\/10.1016\/B978-0-323-91817-6.00001-2.","DOI":"10.1016\/B978-0-323-91817-6.00001-2"},{"key":"3262_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2023.114174","volume":"195","author":"A Sim\u00f5es","year":"2024","unstructured":"Sim\u00f5es A, Veiga F, Vitorino C. Question-based review for pharmaceutical development: an enhanced quality approach. Eur J Pharm Biopharm. 2024;195: 114174.","journal-title":"Eur J Pharm Biopharm"},{"key":"3262_CR31","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1208\/s12248-014-9598-3","volume":"16","author":"LX Yu","year":"2014","unstructured":"Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, Woodcock J. Understanding pharmaceutical quality by design. AAPS J. 2014;16:771\u201383.","journal-title":"AAPS J"},{"key":"3262_CR32","doi-asserted-by":"publisher","first-page":"112965","DOI":"10.1016\/j.jpba.2019.112965","volume":"179","author":"SE Vignaduzzo","year":"2020","unstructured":"Vignaduzzo SE, Maggio RM, Olivieri AC. Why should the pharmaceutical industry claim for the implementation of second-order chemometric models\u2014a critical review. J Pharm Biomed Anal. 2020;179:112965.","journal-title":"J Pharm Biomed Anal"},{"key":"3262_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2024.111875","volume":"207","author":"S Narukulla","year":"2024","unstructured":"Narukulla S, Bogadi S, Tallapaneni V, et al. Comparative study between the full factorial, Box-Behnken, and central composite designs in the optimization of metronidazole immediate release tablet. Microchem J. 2024;207: 111875.","journal-title":"Microchem J"},{"key":"3262_CR34","first-page":"100266","volume":"8","author":"AB Buya","year":"2024","unstructured":"Buya AB, Mahlangu P, Witika BA. From lab to industrial development of lipid nanocarriers using quality by design approach. Int J Pharm X. 2024;8:100266.","journal-title":"Int J Pharm X"},{"key":"3262_CR35","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ijpharm.2019.01.054","volume":"559","author":"BY Gajera","year":"2019","unstructured":"Gajera BY, Shah DA, Dave RH. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology. Int J Pharm. 2019;559:348\u201359.","journal-title":"Int J Pharm"},{"key":"3262_CR36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3109\/10837450.2013.860552","volume":"20","author":"M Casas","year":"2015","unstructured":"Casas M, \u00c1lvarez J, Lucero MJ. Physicochemical stability of captopril and enalapril extemporaneous formulations for pediatric patients. Pharm Dev Technol. 2015;20:271\u20138.","journal-title":"Pharm Dev Technol"},{"key":"3262_CR37","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2146\/ajhp090163","volume":"67","author":"KL Skillman","year":"2010","unstructured":"Skillman KL, Caruthers RL, Johnson CE. Stability of an extemporaneously prepared clopidogrel oral suspension. Am J Health Pharm. 2010;67:559\u201361.","journal-title":"Am J Health Pharm"},{"key":"3262_CR38","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.v69i6.1616","author":"M Friciu","year":"2016","unstructured":"Friciu M, Zaraa S, Leclair G. Stability of extemporaneously prepared Enalapril maleate suspensions in glass bottles and plastic syringes. Can J Hosp Pharm. 2016. https:\/\/doi.org\/10.4212\/cjhp.v69i6.1616.","journal-title":"Can J Hosp Pharm"},{"key":"3262_CR39","unstructured":"International Conference on Harmonisation. Validation of analytical procedures Q2(R2). Geneva: ICH; 2022. Available in: https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q2R2_Document_Step2_Guideline_2022_0324.pdf."},{"key":"3262_CR40","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1208\/s12249-023-02612-w","volume":"24","author":"MA Operto","year":"2023","unstructured":"Operto MA, Maggio R, Leonardi D, Vignaduzzo S. Flexible new dosage forms containing carvedilol for the treatment of patients with cardiovascular disorders: development, stability, palatability, and microbiological studies. AAPS PharmSciTech. 2023;24:159.","journal-title":"AAPS PharmSciTech"},{"key":"3262_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e31581","volume":"10","author":"M Roudbari","year":"2024","unstructured":"Roudbari M, Barzegar M, Sahari MA, Gavlighi HA. Formulation of functional gummy candies containing natural antioxidants and stevia. Heliyon. 2024;10: e31581.","journal-title":"Heliyon"},{"key":"3262_CR42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/jppr.1127","volume":"46","author":"RP Patel","year":"2016","unstructured":"Patel RP, Wanandy T, Zani R, Jose MD, Shastri M, Zaidi STR. Stability of trimethoprim in newly formulated liquid dosage form. J Pharm Pract Res. 2016;46:10\u20134.","journal-title":"J Pharm Pract Res"},{"key":"3262_CR43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/jppr.1612","volume":"50","author":"DP Ellis","year":"2020","unstructured":"Ellis DP, Rozek T, Milne RW. Stability of a compounded oral liquid formulation of clopidogrel for infants. J Pharm Pract Res. 2020;50:321\u20138.","journal-title":"J Pharm Pract Res"},{"key":"3262_CR44","doi-asserted-by":"publisher","unstructured":"Kashinath KP, Sardar MS, Sah SK, Kaity S. Stability and accelerated stability studies of dosage forms. In: Physico-Chemical Aspects of Dosage Forms and Biopharmaceutics. Elsevier; 2024. pp. 19\u201342. https:\/\/doi.org\/10.1016\/B978-0-323-91818-3.00001-3.","DOI":"10.1016\/B978-0-323-91818-3.00001-3"},{"key":"3262_CR45","doi-asserted-by":"publisher","first-page":"100469","DOI":"10.1016\/j.cjac.2024.100469","volume":"53","author":"DK Vemuri","year":"2025","unstructured":"Vemuri DK, Gundla R, Raghupathi JK, Jeedimalla N, Burle GS, Katari NK, Jonnalagadda SB. Development of LC\/LCMS method for estimation of impurities in anti-HIV drug (Bictegravir) using analytical quality by design (AQbD) approach. Chin J Anal Chem. 2025;53:100469.","journal-title":"Chin J Anal Chem"},{"key":"3262_CR46","unstructured":"EMA ICH Q1E Evaluation of stability data - Scientific guideline. 2003. https:\/\/www.ema.europa.eu\/en\/ich-q1e-evaluation-stability-data-scientific-guideline.\u00a0Accessed 20 June 2025."},{"key":"3262_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2025.106915","volume":"108","author":"CS Gurski","year":"2025","unstructured":"Gurski CS, Lazo REL, Gelinsk MA, Alves LA, Sovinsk MS, Sari MHM, Borba HHL, Tonin FS, Pontarolo R, Ferreira LM. Quality by Design applied to pediatric-friendly formulations: a scoping review-based manufacturing process mapping for solid dosage forms. J Drug Deliv Sci Technol. 2025;108: 106915.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3262_CR48","doi-asserted-by":"publisher","first-page":"111940","DOI":"10.1016\/j.biopha.2021.111940","volume":"141","author":"T Waghule","year":"2021","unstructured":"Waghule T, Dabholkar N, Gorantla S, Rapalli VK, Saha RN, Singhvi G. Quality by design (QbD) in the formulation and optimization of liquid crystalline nanoparticles (LCNPs): a risk based industrial approach. Biomed Pharmacother. 2021;141:111940.","journal-title":"Biomed Pharmacother"},{"key":"3262_CR49","first-page":"69","volume":"2","author":"H Jaiswal","year":"2024","unstructured":"Jaiswal H, Ansari MT, Mahmood T, Ahsan F, Ansari VA, Ahmad U. Aceclofenac loaded microspheres: formulation and evaluation of novel preprogrammed drug delivery for the treatment of arthritis. Intell Pharm. 2024;2:69\u201382.","journal-title":"Intell Pharm"},{"key":"3262_CR50","unstructured":"European Medicines Agency. ICH Q1E Evaluation of stability data - Scientific guideline. London: European Medicines Agency; 2003. Available in: https:\/\/www.ema.europa.eu\/en\/ich-q1e-evaluation-stability-data-scientific-guideline."},{"key":"3262_CR51","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/jat.1358","volume":"28","author":"PD Darbre","year":"2008","unstructured":"Darbre PD, Harvey PW. Paraben esters: review of recent studies of endocrine toxicity, absorption, esterase and human exposure, and discussion of potential human health risks. J Appl Toxicol. 2008;28:561\u201378.","journal-title":"J Appl Toxicol"},{"key":"3262_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/nu14071497","volume":"14","author":"\u0141J Walczak-Nowicka","year":"2022","unstructured":"Walczak-Nowicka \u0141J, Herbet M. Sodium benzoate\u2014harmfulness and potential use in therapies for disorders related to the nervous system: a review. Nutrients. 2022;14: 1497.","journal-title":"Nutrients"},{"key":"3262_CR53","doi-asserted-by":"publisher","first-page":"101798","DOI":"10.1016\/j.rechem.2024.101798","volume":"11","author":"L Hejazi","year":"2024","unstructured":"Hejazi L, Mahboubi-Rabbani M, Mahdavi V, Alemi M, Khanniri E, Bayanati M. A critical review on sodium benzoate from health effects to analytical methods. Results Chem. 2024;11:101798.","journal-title":"Results Chem"},{"key":"3262_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16010119","volume":"16","author":"M Bobillot","year":"2024","unstructured":"Bobillot M, Delannoy V, Trouillard A, Kinowski JM, Sanchez-Ballester NM, Soulairol I. Potentially harmful excipients: state of the art for oral liquid forms used in neonatology and pediatrics units. Pharmaceutics. 2024;16: 119.","journal-title":"Pharmaceutics"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03262-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03262-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03262-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T18:05:47Z","timestamp":1770314747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03262-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3262"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03262-w","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no declarations of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"17"}}